Dashboard PDUFA PDUFA History Dilution Watch Downside Radar Missed Milestones Earnings Big Movers Blog

🎤 Upcoming Biotech Conferences

Loading conferences...
Free to browse, no account needed Follow the companies behind these drugs with free AI briefings, catalyst countdowns and dilution alerts.

Soquelitinib · CPI-818, CP-000596

Small molecule · Inhibitor of Interleukin-2 inducible T-cell kinase (ITK) · developed by Corvus Pharmaceuticals

Phase 3 Most advanced trial
CRVS Developer
2 Registered trials

What is Soquelitinib?

Soquelitinib is an orally available, small-molecule, irreversible inhibitor of interleukin-2 inducible T-cell kinase (ITK). It covalently binds cysteine 442 of ITK, disrupting T-cell receptor signaling, and is being studied in T-cell lymphomas.

Summary written with AI from the sources listed at the end of this page.

At a glance

Also known as
CPI-818, CP-000596, CPI-000818, CPI-596
Drug type
Small molecule
Targets
Interleukin-2 inducible T-cell kinase (ITK), Tyrosine-protein kinase TXK (TXK) (secondary target)
Mechanism
Inhibitor of Interleukin-2 inducible T-cell kinase (ITK)
Pathways
T-cell receptor signaling, GATA-3 upregulation / Th2 differentiation
Therapy area
Oncology
Developer
Corvus Pharmaceuticals, Inc. (CRVS)
FDA status
Investigational, not approved in the US. Most advanced trial: Phase 3
UNII
6I5H17AN3I

🧪 Clinical trials

TrialPhaseConditionStatusSponsor
NCT06561048 Phase 3 Peripheral T-Cell Lymphoma, Not Otherwise Specified Recruiting CRVS
NCT03952078 Phase 1 T-cell Lymphoma Active not recruiting CRVS

Trials of the companies BioRadar tracks, from ClinicalTrials.gov, most advanced phase first.

Conditions studied

Angioimmunoblastic T-cell LymphomaFollicular T-Cell LymphomaLymphoma, T-CellLymphoma, T-Cell, PeripheralNodal Peripheral T-Cell Lymphoma With TFH PhenotypePeripheral T-Cell Lymphoma, Not Otherwise SpecifiedSystemic Anaplastic Large Cell LymphomaT-cell Lymphoma

More from Corvus Pharmaceuticals

Sources

Updated Nov 8, 2026. Something wrong or missing? Report it on the CRVS page.

Follow CRVS, the company behind Soquelitinib

See CRVS's upcoming FDA decisions, trial readouts, cash runway and dilution risk, updated every day from SEC, FDA and ClinicalTrials.gov filings.

CRVS catalysts and pipeline →
Data: FDA (Drugs@FDA, Purple Book, DailyMed), NIH (NCI Thesaurus, GSRS, RxNorm), ClinicalTrials.gov • Informational purposes only, not medical or investment advice. • All drugs A–Z

This data is for informational purposes only, not investment advice. BioRadar does not provide buy/sell recommendations. Past performance does not guarantee future results. Always do your own due diligence.